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The Belgian severe asthma registry is a web-based registry encompassing demographic, clin-
ical, functional and inflammatory data of severe asthmatics (SA), aiming at improving aware-
ness, knowledge on its natural history and subphenotypes, and offering tools to optimize care
of this asthma population.
Methods: The cross-sectional analyses of this registry included 350 SA as defined by the ATS
(2000) from 9 Belgian centres, with at least one year follow up.
Results: Mean age was 55  14 yrs. SA were more frequently female (57%) and atopic (70%).
Late-onset asthma (40 yr) was observed in 31% of SA. Current smokers represented 12% while
31% were ex-smokers. In addition to high doses ICS þ LABA, 65% of patients were receiving
LTRA, 27% anti-IgE and 24% maintenance oral corticosteroids (8 mg (Interquartile range-
IQR:4e8) methylprednisolone). Despite impaired airflow (median FEV1:67%; IQR: 52e81) only
65% had a post-bronchodilator FEV1/FVC ratio <70%. The median blood eosinophil count was
240/mm3. The median FENO was 26 ppb (IQR: 15e43) and 22% of SA had FENO  50 ppb.
Induced sputum was successful in 86 patients. Eosinophilic asthma (sputum Eos  3%) was
the predominant phenotype (55%) while neutrophilic (sputum Neu  76%) and paucigranulocy-
tic asthma accounted for 22% and 17% respectively. Comorbidities included rhinitis and chronicMedicine, CHU Sart-Tilman B35, 4000 Liege, Belgium. Tel.: þ32 43667881; fax: þ32 3668846.
.ac.be (F. Schleich).
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1724 F. Schleich et al.rhinosinusitis (49%), nasal polyposis (19%), oesophageal reflux (36%), overweight and obesity
(47%) and depression (19%). In addition, 8% had aspirin-induced asthma and 3% ABPA. Asthma
was not well-controlled in 83% according to ACT < 20 and 77% with ACQ > 1.5.
Conclusion: In this cohort of patients with severe asthma, the majority displayed indices of
persistent airflow limitation and eosinophilic inflammation despite high-dose corticosteroids,
suggesting potential for eosinophil-targeted biotherapies.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
It is recognized that the majority of asthmatics may be
controlled by regular treatment with ICS/LABA. However
there remains a small proportion of patients who do not
respond to this treatment [1,2]. Severe asthma accounts for
a major part of financial burden to health care system
posed by asthma [3]. Refractory asthmatics are patients in
whom alternative diagnoses have been excluded, comor-
bidities have been treated, trigger factors have been
removed and adherence with treatment has been checked.
Patients with severe asthma still have poor asthma control
or frequent severe exacerbations despite intake of high-
intensity treatment or can only maintain adequate control
when taking systemic corticosteroids [4,5]. Severe asthma
is not a single disease but can be divided into several
phenotypes according to inflammatory, clinical and func-
tional characteristics [6]. Those phenotypes may have
prognostic value and therapeutic implications. However,
severe asthma phenotypes have not yet been fully
characterized.
Severe asthma is a poorly understood patho-
physiologically condition and is therefore difficult to
treat. Several severe asthma cohorts and registries re-
ported in the literature aimed to collect data and infor-
mation on severe asthma. The Belgian Severe Asthma
Registry (SAR) is a national Belgian secured web database
for severe asthma, collecting relevant demographic, clin-
ical and social data of severe asthmatics. Here we report
the data collected in the severe asthma population in
Belgium and compare the findings to that of ENFUMOSA [7]
and BIOAIR European study [8], the TENOR study [9], the
SARP study [10] and the UK multicentre registry on re-
fractory asthma [11].
The aim of the registry was to collect epidemiological
and clinical data in order to raise awareness on severe
asthma, to identify several phenotypes, to promote optimal
care for these patients and to be a valuable platform of
patients for testing new drugs in severe asthma.Methods
Selection criteria
After detailed assessment, 350 severe asthmatics (SA) that
fulfilled the American Thoracic Society definition of re-
fractory asthma [12] were recruited between March 2009
and January 2014 from 9 Belgian centres.The Belgian Registry is a secured web database and ad-
mits password protected anonymised data, after fully
informed written consent. Individual centre data can be
downloaded locally by registered users.
Asthma was diagnosed based on symptoms of cough,
breathlessness or dyspnoea together with the demonstra-
tion of airflow variability. The latter was defined by one or
more of the following: increase in forced expiratory volume
in 1s (FEV1) of 12% or greater following inhalation of 400 mg
of salbutamol or inhaled concentration of methacholine
provoking a 20% fall in FEV1 of less than 16 mg/ml. Meth-
acholine challenges were performed according to a stan-
dardized methodology as previously described [13].
SA was defined according to ATS criteria [12]. The defi-
nition requires one major criterion either treatment with
continuous or near continuous (>50% of year) oral cortico-
steroids or requirement for combination high dose ICS
(Beclomethasone or Budesonide > 1000 mg/d,
Fluticasone > 500 mg/d) and Long acting b2 agonists (LABA).
The major criterion has to be associated with at least two
minor criteria: need for additional daily controller medi-
cation in addition to ICS-LABA combinations (Leucotrienes
antagonists (LTRA), theophylline), persistent airway
obstruction (FEV1 < 80% pred, PEF variability > 20%),
asthma symptoms needing short acting b2 agonist on a daily
or near daily basis, one or more urgent care visits for
asthma per year, three or more oral corticosteroids bursts
per year, prompt deterioration with <25% reduction in oral
or ICS use or near fatal asthma event in the past.
The prerequisite for inclusion was age  18 years,
asthma follow-up by a respiratory physician for at least 12
months, education on the disease provided to the patient
and compliance thought to be satisfactory. All the data
presented were collected at the timepoint of recruitment
into the registry.
Demographic, comorbidity and control criteria
Patients were characterised as atopic if they had at least
one positive specific IgE (>0.35 kU/l; Phadia) for at least
one common aeroallergen (cat, dog, house dust mites,
grass pollen, tree pollen and a mixture of moulds) or posi-
tive skin prick tests. Exacerbation in the previous year was
defined by a course of oral corticosteroids for at least 3
days in case of asthma worsening. Nasal polyps and sinusitis
was diagnosed by Ear Nose and Throat specialist either by
endoscopy or Sinus CT scanner. Gastrooesophageal reflux
was diagnosed either by symptoms of heartburn at history
taking or the presence of oesophagitis demonstrated by
Table 1 Demographic, functional, clinical and inflamma-
tory characteristics of severe asthmatics in Belgium.
Patient characteristics
N. 350
Female (%) 57%
Age 55  0.8
Age at onset
<12 years 32%
12e40 years 36%
>40 years 31%
Height, m 167  0.5
Weight, kg 75  0.9
BMI 26 (16e43)
Smoking status
Never 200 (57%)
Ex-smoker 108 (31%)
(pack-years median IQR) (15 (11e24))
Current smokers 40 (12%)
(pack-years median IQR) (11 (10e15))
Atopy, % 70
Current house environment (%)
Country side 39
Suburban area 29
City 31
Unknown 1
FEV1, % pred 68  1.2
FVC, % pred 89  1.1
FEV1/FVC, % 63  0.7
FEV1 reversibility (% from baseline) 11  0.8
FRC (%) (n Z 271) 120  2
RV (%) (n Z 311) 140  2.8
TLC (%) (n Z 305) 102  1.1
DLCO (%) (n Z 273) 78  1.2
KCO (%) (n Z 273) 97  1.3
Airway inflammatory indices
FENO50 (ppb) (n Z 271) 26 (4e250)
Sputum eosinophil count
(%) (n Z 86)
7 (0e92)
Sputum neutrophil count
(%) (n Z 86)
51 (0e99)
Sputum inflammatory
subphenotype (n Z 86)
Paucigranulocytic 17%
Eosinophilic (3%) 55%
Neutrophilic (76%) 22%
Mixed granulocytic 6%
Serum IgE (kU/l) (n Z 295) 207 (2e10,000)
Blood eosinophils (%) (n Z 272) 3 (0e50)
Blood eosinophils (/mm3) (n Z 272) 240 (0e3144)
ACT (n Z 207) 13  0.4
ACQ (n Z 213) 2.57  0.09
AQLQ (n Z 244) 4.14  0.09
ICS dose (BDP mg equivalent/d) 2000 (190e6000)
LABA 91
Anti-histamines, % 26
LTRA, % 65
Anti-cholinergics, % 28
Anti-IgE, % 27
Theophylline, % 22
Maintenance oral corticosteroids, % 24
Table 1 (continued )
Patient characteristics
Specific immunotherapy, % 0.6
Comorbidities (%)
Rhinosinusitis % (Y/N/Ukn) 49% (167/151/32)
Gastrooesophageal reflux (Y/N/Ukn) 36% (124/205/21)
Nasal polyps (Y/N/Ukn) 19% (167/151/32)
Overweight (Y/N/Ukn) 47% (162/173/15)
Psychopathology (Y/N/Ukn) 19% (65/266/19)
Catamenial asthma (Y/N/Ukn) 0.9% (3/340/7)
Aspirin sensitive asthma (Y/N/Ukn) 8% (28/315/7)
Occupational asthma (Y/N/Ukn) 4% (15/328/7)
Churg Strauss syndrom (Y/N/Ukn) 3% (10/333/7)
ABPA (Y/N/Ukn) 3% (11/332/7)
Bronchiectasis (Y/N/Ukn) 16% (54/289/7)
Emphysema (Y/N/Ukn) 7% (24/319/7)
Treatment of comorbidities
Proton pump inhibitors 39%
Anti-depressive/anxiolytics 17%/14%
Intranasal steroids 39%
Oral steroids courses during
previous yr
2.03 (0e7)
Number of hospitalisations
during previous yr
0.95 (0e7) (n Z 113)
Number of hospitalization
during the last three years
1.7 (0e8) (n Z 103)
The Belgian Severe Asthma Registry (BSAR) 1725gastroscopy. Quality of life was assessed using the self-
administered Asthma Quality of Life Questionnaire (AQLQ)
[14] and asthma control by Juniper Asthma Control Ques-
tionnaire (ACQ) [15] and Asthma Control Test (ACT) [16].
Criteria for inflammatory phenotyping
Patients underwent FENO measurement at a flow rate of
50 ml/s according to the ERS/ATS recommendations [17]
(NIOX, Aerocrine, Sweden). Sputum was only induced at
CHU of Liege and processed as previously reported [18,19]
and was successful in 77% of the patients. Cell counts
were carried out on 500 cells after centrifugation (Cyto-
spin) and staining with Diff Quick (Dade, Brussels, Belgium).
We defined an abnormally high sputum neutrophil count as
a percentage >76% (>mean þ 1.7SD of our reference value
found in healthy subjects matched for age) [20].
In a subanalysis we identified patients with type 2-high
and type 2-low inflammation according to the following
criteria: sputum eosinophil count  or <3% [21], exhaled
nitric oxide  or <27 ppb [22] and blood eosinophil
count  or <188/mm3 [20,23].
Statistical analysis
Anonymised data were expressed as mean  SEM for
continuous variables; median and ranges were preferred for
skewed distributions. For categorical variables, the number
of observations and percentages were given in each cate-
gory. Comparisons between different subgroups were per-
formed using one-way analysis of variance (ANOVA) and
Figure 1 Panel A. Education level in severe asthma in
Belgium. Panel B. Employment status in severe asthmatics in
Belgium.
Table 2 Number of hospitalization and steroid bursts in
Belgian severe asthmatics during the previous year.
Number during
the last year
% of patients with
hospitalization
(n Z 106)
% of patients with
systemic corticosteroid
courses (n Z 344)
0 40 (n Z 42) 26 (n Z 90)
1 35 (n Z 37) 15 (n Z 53)
2 19 (n Z 20) 16 (n Z 56)
3 5 (n Z 5) 14 (n Z 48)
>3 2 (n Z 2) 28 (n Z 97)
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cient was used to measure the association between clinical
parameters. The receiver-operating characteristic (ROC)
curve was constructed to determine the cut-off of blood
eosinophil count which best identified a sputum eosinophil
count 3% in severe refractory asthma. Statistical signifi-
cance was taken as p < 0.05.
Results
We recruited 350 SA as defined by the ATS (2000) criteria
from 9 Belgian centres. From those patients, 333 are still
defined as severe asthmatics according to ERS/ATS guide-
lines on severe asthma (2014).
The demographic, functional, clinical and inflammatory
characteristics of severe asthmatics are summarized in
Table 1.
Demographics and treatment characteristics
Female was the predominant gender (57%) and mean age
was 55 yrs. 31% of the severe asthmatics had late-onset
asthma (starting after the age of 40). BMI was slightly
increased (26 kg/m2) and one quarter of the patients had a
BMI > 30. 31% were ex-smokers (64% with at least 10 pack-
yrs) while 12% were current smokers. The prevalence of
atopy was 70%.
One third of Belgian SA lived in cities, one third in sub-
urban area while 39% lived in country side environment.
In addition to high doses of ICS þ LABA, 65% of the pa-
tients received anti-leukotrienes. 24% of severe asthmatics
were treated with systemic corticosteroids on a daily basis,
26% with anti-histamines and 27% with anti-IgE. Theophyl-
line was administered to 22% of the patients and 0.6%
received specific immunotherapy.
Educational level was low in the majority of patients
with 6% quitting school after primary school, 21% after
lower secondary school and 25% after higher secondary
school. Only 16% of severe asthmatics were graduated from
non-university post-secondary school and 6% from univer-
sity (Fig. 1A). Data are unknown in one quarter of the pa-
tients. 36% of SA were employed while 21% were retired
(Fig. 1B).
Comorbidities
Comorbidities were highly prevalent and included chronic
rhinosinusitis (49%), nasal polyposis (19%), oesophageal
reflux (36%), overweight and obesity (47%) and depression
(19%). Bronchiectases diagnosed based on classical CT
criteria were reported in 16% and aspirin sensitive asthma
in 8% of SA while occupational asthma (4%), Churg Strauss
syndrome (3%), ABPA (3%) and catamenial asthma (0.9%)
were less frequent. Emphysema was present in 24 SA (7%)
with 42% of those patients being current smokers, 42% ex-
smokers and 16% non-smokers.
The number of oral steroid courses during the previous
year was 2.03. The number of hospitalisations during the
previous year and the last three years was 0.95 and 1.7
respectively. The detailed description of the number of
hospitalisations and steroid course is descried in Table 2.Patients having a history of hospitalization due to asthma
did not have predominant sputum inflammation feature or
more severe airway obstruction.Lung function
Despite impaired flow rates (mean FEV1, 68%pred; FEV1/
FVC ratio, 63%), 65% of SA had post-bronchodilator FEV1/
FVC ratio < 70%. We found that 60% of SA had FEV1 < 80%
and FEV1/FVC < 70%. The mean reversibility was still 11%
despite patients were on long-acting b2 agonists. 36% of SA
exhibited 12% FEV1 reversibility to 400 mg Salbutamol and
16% of SA had a reversibility 20%.
Severe asthma was associated with significant air trap-
ping. Despite normal total lung capacity (102% pred) there
were signs of air trapping suggested by raised FRC (120% of
Figure 2 Panel A. Distribution of FENO in the population of
severe asthmatics. 49% of SA had FENO levels higher than
27 ppb suggestive of persistant sputum eosinophilic inflam-
mation. Panel B. Distribution of blood eosinophils in severe
asthmatics. 58% had blood eosinophil count 188/mm3.
Figure 4 Distribution of sputum cellular phenotypes in se-
vere asthma (n Z 88). Eosinophilic asthma (3% sputum eo-
sinophils, <76% sputum neutrophils); Neutrophilic asthma (<3%
sputum eosinophils, 76% sputum neutrophils); Pauci-
granulocytic asthma (<3% eosinophils and <76% neutrophils in
induced sputum); Mixed granulocytic asthma (3% eosinophils
and 76% neutrophils in induced sputum).
The Belgian Severe Asthma Registry (BSAR) 1727predicted values) and RV (140% of predicted). DLCO was
slightly impaired (78%) but KCO was well preserved (97%
pred).Inflammatory characteristics
The median FENO value was 26 ppb (4e250 ppb). The
fraction of patients with FENO  50 ppb was 22% (Fig. 2).Figure 3 Correlation between blood eosinophil count
(/mm3) and sputum eosinophil count (%) (p < 0.0001;
r Z 0.53).The median blood eosinophil count was 240/mm3
(Fig. 2). We found an elevated blood eosinophil counts
(>220/mm3) in 53% of SA. Importantly we demonstrated a
significant correlation between blood eosinophil count
(/mm3) and sputum eosinophil count (%) (p-value < 0.0001;
r Z 0.53, Fig. 3).
Sputum was induced in 86 out of 111 patients at CHU of
Liege (success rate of 77%). The median sputum eosinophil
count and sputum neutrophil count was 7% and 51%
respectively. Eosinophilic asthma (sputum Eos  3%) was
the predominant phenotype (55%), while neutrophilic
(sputum Neu  76%) and paucigranulocytic asthma
accounted for 22% and 17% respectively (Fig. 4).Figure 5 ROC curve showing the best cut-off of blood
eosinophil count to identify sputum eosinophil count 3% in
SRA. Sensitivity 72.3%, specificity 72.7%, cut-off: 188/mm3,
p < 0.0001, AUC: 0.745, n Z 80.
Table 3 Comparison of characteristics of smoking versus
nonsmoking severe asthmatics.
Nonsmoking SA
(including
ex-smokers)
Smoking SA
n 308 40
BMI 26.1 24.7
ACQ 2.32 (0e5.86) 3.57 (1.29e5.71)**
ACT 13 (5e25) 11 (5e24)*
AQLQ 4.16 (1.2e7) 3.37 (1.5e6.45)*
Emergency visits 1  0.64 2.17  0.65*
Rescue courses
of oral CS
1.89/patient/yr 1.81/patient/yr
FEV1, % pred 68  21 63  18
Sputum eosinophils 5.5 (0e79)
(n Z 66)
7 (0e92) (n Z 20)
Sputum neutrophils 52 (0e99)
(n Z 66)
47 (0e97) (n Z 20)
Blood eosinophils 280 (0e3144) 167 (0e1677)*
*p < 0.05, **p < 0.01.
1728 F. Schleich et al.By constructing an ROC curve, we found that the blood
eosinophil count was able to identify sputum eosinophil
count 3% with the best cutoff point of 188/mm3 providing
a 72% sensitivity and 73% specificity (nZ 80, AUCZ 0.745,
Fig. 5).
We found a modest but significant correlation between
FENO and sputum eosinophil count (r Z 0.37, p < 0.001)
and between FENO and blood eosinophils (r Z 0.29,
p < 0.0001). By constructing an ROC curve, we found that
the best cutoff of FENO was 28 ppb to identify sputum
eosinophil counts 3% in severe asthmatics.
We assessed the proportion of patients exhibiting
concordant and discordant blood and sputum eosinophilia.
Blood eosinophilia 400/mm3 [24] and sputum eosinophil
count 3% was found in 23% of the patients while exhibiting
elevated sputum eosinophil count without increased blood
eosinophil count was found in 35%. Normal blood and
sputum eosinophil count was common (38%) while isolated
elevation of blood eosinophil count was rare (4%). If we
chose the threshold value of 300/mm3 as recommended
by some authors [21], diffuse eosinophilic inflammation was
found in 36% of the patients, isolated sputum eosinophilic
inflammation was found in 24%, Normal blood and sputum
eosinophil count was common (33%) while isolated blood
eosinophilia was rare (7%).
Asthma control and quality of life
Asthma was uncontrolled in 77% of severe asthmatics as
defined by ACQ score >1.5 and in 83% as defined by ACT
<20.
We found however that 8% had well-controlled severe
asthma (ACQ <0.75) and that 71% of those patients were
women with a high proportion being employed (65%). None
of these patients were current smokers (88% nonsmokers,
12% former smokers). BMI was slightly lower (24 kg/m2)
than in the general SA population and atopy was more
frequent (77%). Quality of life assessed by AQLQ was alsobetter in this sub-population. They had a better lung
function (FEV1 mean: 92%  1.2, FEV1/FVC: 70  0.9) and
fewer signs of air trapping (RV: 120  2.5, FRC: 113  2).
Only 12% were treated with oral corticosteroids. They
exhibited lower FENO levels (17 (5e76)) and lower blood
eosinophil counts (120 (0e1200)).
Characteristics of smoking versus nonsmoking
severe asthmatics
Current smokers with SA had poorer asthma control
assessed by ACQ and ACT as compared to ex- or never
smoking SA. Smoking severe asthmatics had more frequent
unscheduled health care visits than exsmokers or never
smokers with SA and exhibited lower levels of blood eo-
sinophils (Table 3).
Relationship between lung function, inflammation,
asthma control and quality of life
Average AQLQ was 4.14 (1.2e7). We found a positive cor-
relation between FEV1 and AQLQ (rZ 0.21, p < 0.0001) and
an inverse correlation between FEV1 and ACQ (r Z 0.49,
p < 0.0001). We did not find any significant correlation
between blood eosinophils or sputum eosinophil count and
AQLQ (r Z 0.01, p Z 0.8; r Z 0.06, p Z 0.58 respec-
tively) or between blood eosinophils or sputum eosinophils
and ACQ (rZ 0.02, pZ 0.8; rZ 0.06, pZ 0.57). We did
not find any significant correlation between BMI and ACQ or
AQLQ.
Type 2-high versus type 2-low criteria for targeted
therapy
The median total serum IgE level was 207 kU/l and 58% of
SA with atopic status exhibited IgE levels between 76 and
700 kU/l, the range to possibly consider treatment with
omalizumab in Belgium [25]. In nonatopic SA, 48% had IgE
levels between 76 and 700 kU/l. Detailed data on sensiti-
zation were available in the Liege cohort (n Z 111) where
45% of SA were atopic to house dust mite, 39% to cat, 31% to
dog, 29% to grass pollen, 23% to birch pollen, 21% to moulds
and 12% to horse. According to Belgian’s reimbursement
criteria, treatment with omalizumab could be proposed in
27% of SA in Liege.
In the DREAM study [21], asthmatics had a history of 2 or
more exacerbations requiring systemic corticosteroids in
the previous year. Additionally, they had evidence of
eosinophilic inflammation as shown by one or more criteria:
a sputum eosinophil count of 3%, FENO  50 ppb, blood
eosinophils 300/mm3 or prompt deterioration of asthma
control after a 25% or less reduction in regular maintenance
ICS or OCS. According to these criteria [21], 106 patients
(30%) of this cohort could reveal eligible for anti-IL5
therapy.
We further classified our SA into inflammatory pheno-
types according to evidence of either sputum eosinophil
count 3% or the presence of both exhaled nitric oxide
27 ppb and blood eosinophil count 188/mm3. We found
that 57% of SA fulfilled those criteria (Fig. 6). Eosinophilic
SA was more frequently associated with chronic
Figure 6 Classification of SA in Th2-high versus Th2-low
phenotype according to sputum eosinophil count (or <3%),
FENO levels (or <27 ppb), and blood eosinophil count (or
<188/mm3). SA were classified as Th2-high phenotype if
induced sputum showed 3% eosinophils or FENO levels
27 ppb and blood eosinophil count 188/mm3 while Th2-low
was chosen if induced sputum eosinophilc count was <3% or
FENO and Blood eosinophil count were <27 ppb and <188/mm3
respectively. 169 patients were classified in eosinophilic and
non eosinophilic asthma according to this definition and further
characterized as early (<12 yrs), intermediate (12e40 yrs) or
late onset (>40 yr). *181 patients were unclassified due to the
lack of information on induced sputum, FENO or blood eosin-
ophil count or discordant FENO and blood eosinophils
information.
The Belgian Severe Asthma Registry (BSAR) 1729rhinosinusitis (65%) and nasal polyps (24%) in case of late
onset asthma compared to 52% and 18% in early onset
asthma.Discussion
Our data confirm that the majority of severe asthmatics are
female and atopic. Moreover we have shown that asthma
started after 12 yrs in two third of SA and that SA exhibited
increased airway eosinophilic inflammation compared to a
general population of asthmatics [20]. Dominant comor-
bidities were chronic rhinosinusitis, overweight and gas-
trooesophageal reflux. Type 2-high and Type 2-low SA were
diagnosed based on induced sputum, blood eosinophil
count, IgE and FENO levels. A trait suggesting type 2-high
was identified in the majority of SA despite treatment
with high doses of ICS (and oral corticoids in a subgroup).
Demographic and general clinical data
Our data confirm the usual female preponderance
[10,11,26,27]. In comparison with a general population of
asthmatics [28], SA was rather similar in age (55 vs 52). Late
onset asthma, starting after the age of 40, was observed in
31% of patients. The proportion of current smokers was
higher than that observed in UK registry [11] (12% vs 6%)
while 31% of our population recognised past smoking history(similar to UK registry). The study of Thomson [29] showed
similar data with 9% of British severe asthmatics being
current smokers, while 28% were ex-smokers and 62% never
smokers (for detailed comparison with other registries, see
online supplement). In this study, current smokers with SA
had poorer asthma control and more unscheduled health
care visits than exsmokers or never smokers. BMI was
slightly increased but remained in the non-obese range in
the majority of patients (only one quarter had BMI > 30)
and was similar to that observed in the general population
of asthmatics [28], in UK registry [11], ENFUMOSA [7] and
BIOAIR studies [8]. Severe asthmatics in Belgium have
rather low level of education with only 22% graduated from
post-secondary school. Our interpretation is that asth-
matics with low level of education are more prone to be
exposed to noxious particles, massive allergen amount in
their daily life because being less cautious in taking care of
their health.
Less than 40% of severe asthmatics are still profession-
ally active. This was similar to what was observed in UK
where 53.4% were not working [11]; ENFUMOSA study [30]
concluded that fewer severe asthma patients than mild
asthma patients were currently employed.
Treatment and comorbidities
In addition to high doses ICS-LABA, SA in Belgium received
more frequently LTRA and omalizumab than in UK [11]
while theophylline and oral corticosteroids were less
commonly encountered than in UK registry and ENFUMOSA.
The higher number of anti-IgE treated patients in our reg-
istry is probably due to the inclusion of a high number of
Belgian severe refractory asthmatics in the PERSIST study
[31]. For the management of comorbidities, intranasal
corticosteroids and proton pump inhibitors (PPI) were more
frequently prescribed in Belgium than in UK [11].
The number of oral steroids courses during the year
preceding inclusion in the SA was lower than that observed
in the UK register [11] while the number of hospitalisations
was higher.
The dominant comorbidities encountered in the Belgian
severe asthma population were rhinosinusitis, overweight
and gastrooesophageal reflux. The proportions were similar
to previously reported [11] except for chronic rhinosinusitis
that was more frequently encountered in Belgium. The
treatment of rhinosinusitis by nasal corticosteroids is in
accordance with the high proportion of rhinitis observed in
a large population of asthmatics in Belgium [32]. We found
a similar proportion of occupational asthma and aspirin-
sensitive asthma in our cohort as compared to UK cohort
[11].
Lung function
Overall there was a moderate obstructive airway pattern.
The obstruction level was similar to ENFUMOSA [7] and UK
register [11] but lower than in SARP study [10]. Surprisingly,
several patients with normal FEV1 were included in the
registry due to high respiratory symptoms despite high-dose
ICS. Those are patients who still report symptoms and
bronchodilator use despite good airway function. Although
1730 F. Schleich et al.we can not exclude that these patients exhibit persistent
bronchial hyperresponsiveness, they might have “discor-
dant disease” [33] as their indices of airway inflammation
were low (median FENO 22 ppb, median sputum eosinophils
2.4%). 59% of these SA with normal FEV1 had obesity and
late onset disease (>40 yrs) with similar characteristics as
“obese non-eosinophilic” asthma reported by Haldar et al.
As in UK registry [11] and ENFUMOSA study [7], the co-
efficient transfer was well preserved in our population
which can be considered as a sign that our asthmatics are
well different from COPD patients even if the majority of
our patients displayed fixed airway obstruction. The normal
KCO suggests a preserved alveolocapillary membrane. We
confirmed that severe asthma is associated with significant
increase in air trapping with normal total lung capacity
suggesting involvement of small airways [1,10,34].Inflammatory subphenotypes
The frequency of atopy remained high despite two thirds of
SA having onset of asthma after the age of 12 yrs. Atopy was
similar to that observed in SARP study [10] but higher than
in BIOAIR study [8], ENFUMOSA [7] and UK registry [11].
SARP data and ours are based on skin prick tests and/or
specific IgE level while in the UK registry it was based on the
history, which may have led to underestimation.
The median FENO value is in the lower part of the grey
zone (25e50 ppb [35]) in severe asthma. This is probably
due to higher doses of inhaled corticosteroids in this sub-
population. This is suggesting the persistence of an airway
inflammatory process since we were able to show that in
patients receiving high dose ICS the FENO threshold pre-
dicting sputum eosinophil count 3% was shown to be
27 ppb [22]. 49% of severe asthmatics exhibited FENO levels
>27 ppb suggesting an eosinophilic phenotype. As
compared to UK register [11], SARP [10] and BIOAIR [8],
FENO levels were lower in our register.
Our median blood eosinophil count was slightly lower
than that observed in the UK register [11]. The blood
eosinophil count threshold that best predicts the presence
of uncontrolled airway eosinophilia in SA was found to be
188/mm3. According to this threshold, 58% exhibited
eosinophilic asthma.
The data related to sputum were only available for the
series of patients from CHU of Liege. We found a success
rate of sputum induction of 77%, as usually reported in
asthma [20]. The raised airway granulocytic inflammation is
a common finding [36]. The median sputum eosinophil
count was higher than that observed in the UK cohort [11].
We found a lower proportion of paucigranulocytic asthma in
the severe asthma population than the 40% observed in the
general population of asthmatics [20]. Eosinophilic asthma
was more frequent in severe asthma (55% vs 41%) and
neutrophilic asthma followed the same picture (21% vs 16%
in the general population of asthmatics). Duncan [37] has
demonstrated that reduced eosinophil apoptosis and
increased sputum eosinophilia both significantly correlate
with asthma severity. Neutrophilic inflammation was found
to be increased in severe asthma [38]. It has been sug-
gested that this could be due to a protection of neutrophils
from apoptosis by corticosteroids. The mixed granulocyticasthma was twice more frequent in SA. Eosinophilic asthma
was more frequently encountered in late onset asthma in
line with previous reports [39].
Asthma was uncontrolled in 77% of severe asthmatics
according to ACQ. The 8% well controlled severe asthmatics
were nonsmoking patients with higher rate of atopy,
receiving high doses corticosteroids and exhibiting less se-
vere airway obstruction and fewer respiratory symptoms.
They had less intense eosinophilic inflammation.
Correlation between clinical and inflammatory data
We found a correlation between asthma control and airway
calibre, a fact that has already been observed in asthma in
general [40,41]. There was a weak correlation between
quality of life and airway calibre. A similar correlation be-
tween FEV1 and AQLQ has already been demonstrated in a
large population of persistent asthmatics [42]. We did not
find any significant correlation between systemic eosino-
philic inflammation and asthma control or quality of life. In
a previous study conducted in a large population of unse-
lected asthmatics [28], we did not find any significant
correlation between ACQ and blood eosinophil count while
there was a weak correlation between ACQ and sputum
eosinophil count. The fact that we did not find any corre-
lation between blood eosinophil count or sputum eosinophil
count and AQLQ is in line with DREAM study, as anti-IL5
therapy were able to decrease sputum and blood eosino-
phil count but were not associated with an improvement in
AQLQ [43] in severe eosinophilic asthmatics compared with
placebo.
BMI was correlated neither with ACQ nor with AQLQ in
our severe asthma population. Median BMI in our Belgian
severe asthma population is rather similar to BMI found in a
general population of asthmatics [20,28]. Lavoie et al.
previously failed to find any association with asthma
severity, which is consistent with the present findings [44].
Therefore BMI might not be a critical factor in severe
asthmatics as there are several other factors influencing
asthma control in this population.
Therapeutic implications
We found elevated levels of IgE in our population of severe
asthmatics whatever the atopic status. For the manage-
ment of severe asthma in Belgium, the only biological
treatment already commercially available is anti-IgE,
reimbursed in case of sensitization to perennial allergen
and a level of IgE comprised between 76 and 700 kU/l. The
median IgE was higher in our register than that observed in
UK register [11], ENFUMOSA [7] and SARP [10].
The majority of patients have residual eosinophilic
inflammation both at systemic and airway level and are
therefore potential candidates for anti-IL5 treatment. In
the DREAM study [21], asthmatics had a history of 2 or more
exacerbations requiring systemic corticosteroids in the
previous year. Additionally, they had evidence of eosino-
philic inflammation as shown by one or more criteria: a
sputum eosinophil count of 3%, FENO of 50 ppb or more,
blood eosinophils of 300/mm3 or more or prompt deterio-
ration of asthma control after a 25% or less reduction in
The Belgian Severe Asthma Registry (BSAR) 1731regular maintenance ICS or OCS. We identified 30% poten-
tial candidates for anti-IL5 therapy according to DREAM
criteria [21]. However taking into account the adapted
threshold (for FENO and blood eosinophil count) to identify
eosinophilic inflammation in asthmatics treated with high
doses ICS, 57% of patients had eosinophilic asthma.
Although the mechanism of action of bronchial thermo-
plasty is not currently completely understood, this bron-
choscopy technique seems to act on smooth muscle mass.
Thermoplasty could emerge as a therapeutic option in SA
who exhibit high bronchodilatation after salbutamol (16% of
SA in our registry). The role of macrolides in non-
eosinophilic severe asthma [45] remains to be clarified in
larger studies.
For the recruitment of Belgian SA, we followed 2000 ATS
criteria [12] because the collection of data started in 2009.
Our study limitations are the limited number of patients
with detailed allergic characteristics and induced sputum
analysis and the recruitment at tertiary care University
hospitals with potential selection bias.Conclusion
In this Belgian cohort of patients with SA, we show that
atopic background and eosinophilic inflammation represent
the predominant features. Findings are consistent with
other European and American registries, and will help to
identify candidates for upcoming targeted therapeutic ap-
proaches. Further studies are also needed to clarify
whether particular endotypes could be identified in this
heterogeneous group of asthma patients with severe dis-
ease that is refractory to current therapies.Listing of the contributions
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